STOCKHOLM, November 26, 2015 /PRNewswire/ --
Juntendo University Hospital sees the potential to use SyMRI to find optimal contrast weighting of MRI for patients with Multiple Sclerosis (MS) or brain tumor metastases, and has signed a research agreement with SyntheticMR in order to use SyMRI in clinical research projects at the hospital. Using SyMRI, it is possible to generate multiple contrast images from a single scan and adjust the parameter settings after the patient has left, thus making it possible to both fine tune images and recreate additional contrasts that may otherwise have been missed.
"We particularly appreciate the power of changing the contrast after the scan, which we anticipate will be useful in finding the most suitable contrast settings for each patient. We will initially use SyMRI in research projects related to MS and brain tumor metastases, with the aim of later taking it into clinical practice at the hospital," says Professor Aoki at Juntendo University Hospital.
Compared to conventional MRI, SyMRI uses a fundamentally different approach as it measures tissue properties and synthesizes images based on absolute measurement of these properties rather than generating a fixed contrast image. Thus it is possible to generate several contrast images from the same 3-6 minutes scan, significantly shortening the scan time compared to acquiring each contrast separately. With a free choice of TE, TR and TI after the scan, it is possible to recreate any T1-weighted, T2-weighted, FLAIR or Inversion Recovery image.
SyMRI Research Edition is optimized for clinical research within neuro imaging and includes exportable SyMaps, quantitative T1, T2 and PD maps. SyMaps can be saved and exported for further analysis in other formats.
The agreement with Juntendo University Hospital includes a license of SyMRI Research Edition for research use at the hospital.
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has devloped SyMRI®, delivering multiple, adjustable contrast images and quantitative data from one 3-6 minutes scan. SyMRI IMAGE provides fast MRI workflows, allowing high patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI Research Edition includes exportable SyMaps™, quantitative T1, T2 and PD maps of the brain, allowing the investigation to be taken even further. SyMRI is CE-marked. SyMRI is a registered trademark in Europe and in the USA. For additional information, please visit http://www.syntheticmr.com .
Contact: Maria Wrethag, CMO and Head of Investor relations SyntheticMR AB, +46-76-119-1983
SOURCE SyntheticMR AB